RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $4.00 Average Price Target from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been given a consensus recommendation of “Hold” by the seven analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $4.00.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of RAPT Therapeutics in a report on Monday, March 10th.

Institutional Trading of RAPT Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Simplicity Wealth LLC bought a new position in RAPT Therapeutics during the first quarter valued at about $25,000. Picton Mahoney Asset Management increased its position in shares of RAPT Therapeutics by 994.4% during the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after purchasing an additional 14,697 shares during the period. JPMorgan Chase & Co. raised its stake in shares of RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in RAPT Therapeutics in the fourth quarter worth $63,000. Finally, Sei Investments Co. acquired a new stake in RAPT Therapeutics during the fourth quarter worth $64,000. 99.09% of the stock is currently owned by institutional investors and hedge funds.

RAPT Therapeutics Price Performance

NASDAQ RAPT opened at $0.77 on Friday. RAPT Therapeutics has a fifty-two week low of $0.75 and a fifty-two week high of $4.83. The stock’s 50-day moving average is $1.03 and its two-hundred day moving average is $1.25. The firm has a market cap of $101.65 million, a P/E ratio of -0.28 and a beta of -0.04.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.23. On average, equities analysts expect that RAPT Therapeutics will post -2.14 EPS for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.